Study Shows Experimental Ebola Vaccine Appears Promising; Large Trial Begins In West Africa

The Atlantic: Ebola Vaccine Appears Safe, Effective
“Tests of an experimental Ebola vaccine have found that 100 percent of vaccinated people mounted a promising immune response and incurred no serious side effects, according to results published [Thursday] morning in The New England Journal of Medicine…” (Hamblin, 4/2).

Daily Mirror: ‘Successful’ Ebola vaccine administered in crisis countries Guinea, Sierra Leone and Liberia
“An Ebola jab is being given to people living in the West African areas hit most by the virus after human trials in unaffected countries proved successful. Scientists hope immunization is possible with just one injection after ‘highly promising results’ in the first 138 healthy adults who were vaccinated with various doses…” (4/2).

Wired: Ebola vaccine reaches West Africa for massive human trial
“A 27,000-person trial of an Ebola vaccine tested by a London university has started in West Africa. The number of volunteers involved in the trial just tops the number of people that have been infected with the vicious disease since the outbreak began – a harrowing 25,178…” (Clark, 4/2).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270 | Email Alerts: | |

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.